CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem ...

May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an ...

Nano-cap U.S. biotech Spero Therapeutics (NASDAQ:SPRO) added ~255% in the premarket on Wednesday after the company and its partner GSK (NYSE:GSK) announced that tebipenem HBr, their oral treatment ...

May 28 (Reuters) - Spero Therapeutics (SPRO.O), opens new tab and partner GSK (GSK.L), opens new tab are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...

Shares of Spero Therapeutics gained after the company and GSK ended their trial for a treatment for complicated urinary tract infections early after it met its primary endpoint. The stock more ...

Spero’s stock price was up 245.89% at last check Wednesday following the news. The decision follows a recommendation from an Independent Data Monitoring Committee (IDMC) based on a planned ...

GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh phase 3 readout. The trial of 1,690 hospitalized patients with ...

Spero and GSK plan to work with U.S. regulatory authorities to include the data as part of a filing with the FDA in the second half of 2025. The development of tebipenem HBr has been partially ...